Dr. Falk Pharma acquires Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and...